ESTEVE ANNOUNCES POSITIVE RESULTS FROM ITS PHASE II CLINICAL STUDY OF E-58425 IN ACUTE PAIN
The results of the study, in patients with acute postoperative moderate to severe pain, show that E-58425 demonstrated superior efficacy and safety over both placebo and a standard of care
E-58425 is a novel, first-in-class, patented, co-crystal product entity
The positive phase II data confirm the Product Concept of E-58425: Clinically relevant and robust pain relief achieved at low doses of E-58425 associated with a better safety & tolerability profile and risk-benefit ratio.
ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain, today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.
E-58425 is a patented new product co-crystal entity of two active pharmaceutical ingredients (APIs). Phase I clinical testing demonstrated that the new co-crystal entity exhibited distinct and optimized pharmacokinetic properties with respect to those of the simple co-administration of the two individual APIs, thus strongly differentiating E-58425.
The positive phase II data presented here confirm that E-58425 delivers synergistic efficacy accompanied by an excellent safety and tolerability profiles.
The study (420 patients) was randomized, double-blind, and controlled with Placebo and Tramadol (100 mg) in parallel groups in the post-operative management of moderate to severe pain following extraction of two or more impacted third molars requiring bone removal. The study was designed to evaluate the effective doses among four strengths of E-58425 (50 mg, 100 mg, 150 mg and 200 mg), and compared with Placebo and Tramadol. All of the dosage strengths of E-58425 tested contained amounts of the individual APIs that would be considered sub-therapeutic in the moderate to severe pain model used.
The results of the trial, in a complex pathophysiology pain model, show that:
- The 100 mg, 150 mg and 200 mg doses of E-58425 were associated with a dose dependent, statistically significant and clinically relevant superior analgesic activity in the primary endpoint (sum of pain intensity differences at 8 h) versus Placebo (P < 0.002 for all three E-58425 doses).
- The 100 mg, 150 mg and 200 mg doses of E-58425 were also associated with a dose dependent, statistically significant and clinically relevant superior analgesic activity in the primary endpoint versus Tramadol 100 mg (P < 0.02 for all three E-58425 doses). The 50 mg dose of E-58425 also exerted superior efficacy compared to the 100 mg Tramadol comparator; however this result was not statistically significant.
- There was also a faster onset of action, longer duration of analgesia, and less need for rescue medication with E-58425.
- Regarding safety and tolerability, 50 mg and 100 mg doses of E-58425 showed a frequency of treatment emergent adverse events (TEAEs) very similar to placebo, while the 150 mg dose of E-58425 was associated with 50% less TEAEs (in both % of patients with AEs as well as AE count) compared to Tramadol 100 mg.
The overall Phase II results support the Product Concept of E-58425: Clinically relevant and robust pain relief achieved at low doses of E-58425 (hence low dose of each active ingredient) associated with a better safety & tolerability profile and risk-benefit ratio. Therefore, E-58425 has demonstrated a strong improvement in efficacy and has significantly improved the risk-benefit ratio compared to that expected for the individual components.
The results also support that while both active ingredients act via different complementary central and peripheral mechanisms of action for synergy in efficacy, they have little or no overlap in safety, tolerability and metabolism, and therefore, neither unpredictable safety concerns nor clinically relevant drug-drug interactions between the active principles are expected.
ESTEVE is currently seeking partners to support the further development of E-58425 in both acute and chronic moderate to severe pain.
R&D at ESTEVE (www.esteve.com/research-development)
ESTEVE's dedicated in-house R&D team is focused on the development of novel pain medicines, an area of high unmet medical need.
In addition to E-58425, ESTEVE has a number of projects in different stages of development including those that target the Sigma-1 receptor, an area in which the company has accumulated world-leading know-how and expertise. The most advanced project, E-52862, currently in Phase II clinical testing, is a potent and highly selective Sigma-1 receptor antagonist that represents a novel approach and a new mechanism of action for pain in a field with a significant need for new therapies. Additionally, E-52862 could have potential applications in other neurological and psychiatric indications.
E-58425 and E-52862 have been supported by The Spanish Ministry of Economy and Competitiveness.
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more